The specific chymase inhibitor TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice

Experimental Lung Research

Volumn 37, Issue 2, 2011, Pages 101-108

  Takato, Hazuki ^a   Yasui, Masahide ^a   Ichikawa, Yukari ^a   Waseda, Yuko ^a   Inuzuka, Kanako ^a   Nishizawa, Yoriko ^a   Tagami, Atsuro ^a   Fujimura, Masaki ^a   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

chymase inhibitor; lung fibrosis; neutrophil; silica

Indexed keywords

2 [4 [5 FLUORO 3 METHYLBENZO(B)THIOPHEN 2 YL]SULFONAMIDO 3 METHANESULFONYLPHENYL]THIAZOLE 4 CARBOXYLIC ACID; CHYMASE INHIBITOR; HYDROXYPROLINE; MACROPHAGE INFLAMMATORY PROTEIN 2; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 4; SILICON DIOXIDE; TRANSFORMING GROWTH FACTOR BETA1; TY 51469; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COMPOSITION; CELL MIGRATION; CONTROLLED STUDY; LUNG FIBROSIS; LUNG LAVAGE; MALE; MOUSE; NEUTROPHIL; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; SILICOSIS;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINE CCL2; CHEMOKINES, CC; CHYMASES; CYTOKINES; HYDROXYPROLINE; MACROPHAGE INFLAMMATORY PROTEINS; MALE; MAST CELLS; MICE; MICE, INBRED ICR; NEUTROPHILS; PULMONARY FIBROSIS; SERINE ENDOPEPTIDASES; SILICON DIOXIDE; SULFONAMIDES; THIOPHENES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79951907179     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2010.520815     Document Type: Article

References (35)

1. Schwartz LB, Austen KF, et al: Enzymes of the mast cell granule. J Invest Dermatol. 1980;74:349-353. (Pubitemid 10034235)
2. Welle M, et al: Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J Leukoc Biol. 1997;61:233-245. (Pubitemid 27149902)
3. Takai S, et al.: A novel chymase inhibitor, 4-[1-([bis-(4-methylphenyl)- methyl]-carbamoyl)3-(2-ethoxy-benzyl)-4-oxo-a zetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther. 2003;305:17-23. (Pubitemid 36373831)
4. Matsumoto T, et al.: Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. 2003;107:2555-2558. (Pubitemid 36628935)
5. Takai S, et al.: A single treatment with a specific chymase inhibitor, TY-51184, prevents vascular proliferation in canine grafted veins. J Pharmacol Sci. 2004. 94:443-448. (Pubitemid 38590765)
6. Takai S, Miyazaki M, et al: Effect of chymase inhibitor on vascular proliferation. Jpn J Pharmacol. 2002;90:223-227. (Pubitemid 35422940)
7. Shiota N, et al.: Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice. Br J Pharmacol. 2005;145:424-431. (Pubitemid 40966271)
8. Watanabe N, et al.: Chymase inhibitor improves dermatitis in NC/Nga mice. Int Arch Allergy Immunol. 2002;128:229-234. (Pubitemid 34765229)
9. Sakaguchi M, et al.: A specific chymase inhibitor,NK3201, suppresses bleomycin-induced pulmonary fibrosis in hamsters. Eur J Pharmacol. 2004;493:173-176. (Pubitemid 38746947)
10. Tomimori Y, et al.: Involvement of mast cell chymase in bleomycin-induced pulmonary fibrosis in mice. Eur J Pharmacol. 2003;478:179-185. (Pubitemid 37315737)
11. Balcells E, et al.: Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol. 1997;273:H1769-1774.
12. Miyazaki M, et al.: Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther. 2006;112:668-676. (Pubitemid 44573489)
13. Sukenaga Y, et al.: Development of the chymase inhibitor as an anti-tissue-remodeling drug: myocardial infarction and some other possibilities. Jpn J Pharmacol. 2002;90:218-222. (Pubitemid 35422939)
14. Palaniyandi SS, et al.: Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats. Exp Biol Med (Maywood). 2007;232:1213-1221. (Pubitemid 47503062)
15. He S,Walls AF, et al: Human mast cell chymase induces the accumulation of neutrophils, eosinophils and other inflammatory cells in vivo. Br J Pharmacol. 1998;125:1491-1500.
16. Takai S, et al.: Chymase inhibition provides pancreatic islet protection in hamsters with streptozotocin-induced diabetes. J Pharmacol Sci. 2009;110:459-465.
17. Tashiro K, et al.: Chymase inhibitor prevents the nonalcoholic steatohepatitis in hamsters fed a methionine- and cholinedeficient diet. Hepatol Res. 2010;40:514-523.
18. Komeda K, et al.: Chymase inhibition attenuates tetrachloride-induced liver fibrosis in hamsters. Hepatol Res. 2010;40: 832-840.
19. Kakimoto K, et al.: Significance of chymase-dependent matrix metalloproteinase-9 activation on indomethacin-induced small intestinal damages in rats. J Pharmacol Exp Ther. 2010;332:684-689.
20. Ashcroft T, Simpson JM, Timbrell V, et al: Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41:467-470. (Pubitemid 18098428)
21. Schrier DJ, Phan SH, McGarry BM, et al: The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation. Am Rev Respir Dis. 1983;127:614-617.
22. Wang X, et al.: Silencing CD36 gene expression results in the inhibition of latent-TGF-beta1 activation and suppression of silica-induced lung fibrosis in the rat. Respir Res. 2009;10:36.
23. Tchougounova E, Pejler G, Abrink M, et al: The chymase, mousemast cell protease 4, constitutes themajor chymotrypsinlike activity in peritoneum and ear tissue. A role for mouse mast cell protease 4 in thrombin regulation and fibronectin turnover. J Exp Med. 2003;198:423-431. (Pubitemid 36976053)
24. Tani K, et al.: Chymase is a potent chemoattractant for human monocytes and neutrophils. J Leukoc Biol. 2000;67:585-589.
25. Terakawa M, et al.: Mast cell chymase induces expression of chemokines for neutrophils in eosinophilic EoL-1 cells and mouse peritonitis eosinophils. Eur J Pharmacol. 2006;538:175-181.
26. Nakao A, et al.: Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest. 1999;104:5-11. (Pubitemid 29534339)
27. Hirata K, et al.: Enhanced mast cell chymase expression in human idiopathic interstitial pneumonia. Int J Mol Med. 2007;19:565-570.
28. Mitani Y, et al.: Mast cell chymase in pulmonary hypertension. Thorax. 1999;54:88-90. (Pubitemid 29103760)
29. Pesci A, et al.: Mast cells in fibrotic lung disorders. Chest. 1993;103:989-996. (Pubitemid 23110259)
30. Gersch C, et al.: Mast cells and macrophages in normal C57/BL/6 mice. Histochem Cell Biol. 2002;118:41-49. (Pubitemid 34762318)
31. Suzuki N, et al.: Mast cells are essential for the full development of silica-induced pulmonary inflammation: a study with mast cell-deficient mice. Am J Respir CellMol Biol. 1993;9:475-483. (Pubitemid 2007500)
32. He S, Walls AF, et al: The induction of a prolonged increase in microvascular permeability by human mast cell chymase. Eur J Pharmacol. 1998;352:91-98. (Pubitemid 28359412)
33. Adamson IY, Prieditis H, Bowden DH, et al: Instillation of chemotactic factor to silica-injected lungs lowers interstitial particle content and reduces pulmonary fibrosis. Am J Pathol. 1992;141:319-326.
34. Adamson IY, Prieditis H, Bowden DH, et al: Enhanced clearance of silica from mouse lung after instillation of a leukocyte chemotactic factor. Exp Lung Res. 1994;20:223-233. (Pubitemid 24205004)
35. Okamoto Y, Takai S, Miyazaki M, et al: Effect of chymase-dependent transforming growth factor beta on peritoneal adhesion formation in a rat model. Surg Today. 2004;34:865-867. (Pubitemid 39331210)